Mana Communications
Stories naming Caleb Hulme-Moir. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
The MRCF, managed by publisher Brandon Capital, has launched a government-funded national biotech incubator with committed funding, and appointed a new Head of Operations, with applications now open for its first intake.
Glyscend Therapeutics, a Johns Hopkins spin-out, is starting a Phase I trial of its type 2 diabetes pill in Adelaide; the piece recalls its AUD$29 million Series A led by Brandon Capital's MRCF.
Also Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio
Brandon Capital led a NZ$14 million investment in Amaroq Therapeutics, a University of Otago spinout developing RNA cancer therapies, with three co-investors and a Callaghan Innovation repayable grant supporting the deal.
University of Otago cancer RNA spinout Amaroq Therapeutics has raised NZ$14 million led by Brandon Capital with Otago Innovation, NZ Innovation Booster and Cure Kids Ventures to advance its lncRNA-targeting cancer therapies.
Also Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio
IP lawyer Kylie Diwell joins the board of the Brandon Capital-managed MRCF. She argues research commercialisation needs skilled teams, while MRCF leaders welcome government innovation support and urge patent box tax reform for biotech.